Related Experiment Video
Updated: Jun 19, 2026
06:12
Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis
Published on: January 11, 2014
Spinal muscular atrophy: molecular mechanisms
M A Farrar1, H M Johnston, P Grattan-Smith
1Department of Neurology, Sydney Children's Hospital, Sydney, Australia.
Current Molecular Medicine
|October 29, 2009
Summary
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder causing motor neuron degeneration. Current research explores SMN protein function and potential therapeutic targets for this debilitating condition.
Area of Science:
- Neurology
- Genetics
- Molecular Biology
Background:
- Spinal muscular atrophy (SMA) is a common, autosomal recessive neuromuscular disorder.
- It is characterized by muscle weakness and atrophy due to motor neuron degeneration.
- No effective treatments are currently available, leading to severe physical disability and reduced lifespan.
Purpose of the Study:
- To review the clinical manifestations, molecular genetics, diagnosis, pathogenesis, and emerging therapeutic strategies for SMA.
- To highlight the molecular and diagnostic complexities through a clinical case.
- To discuss unresolved issues regarding motor neuron vulnerability and primary pathogenesis.
Main Methods:
- Review of existing literature on SMA.
- Analysis of molecular genetics and diagnostic approaches.
- Discussion of potential therapeutic targets based on SMN genomic organization.
Main Results:
- SMA is primarily caused by homozygous disruption of the SMN1 gene, leading to insufficient SMN protein.
- Diagnosis is typically achieved through genetic testing, though complexities exist.
- Recent advances have identified potential therapeutic targets.
Conclusions:
- Understanding SMN protein function and SMA pathogenesis is advancing.
- Further research is needed to determine the selective vulnerability of motor neurons and the timing of pathogenesis.
- Novel therapeutic strategies are under development for SMA.
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:26Cross-bridge Cycle
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...